We are live on ! Find out more
BLCM

Bellicum Pharmaceuticals, Inc.

Delisted

BLCM was delisted on the 1st of June, 2023.

92 hedge funds and large institutions have $68.7M invested in Bellicum Pharmaceuticals, Inc. in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 23 increasing their positions, 29 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% more call options, than puts

Call options by funds: $38K | Put options by funds: $34K

8% less funds holding

Funds holding: 10092 (-8)

21% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 29

33% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 21

54% less capital invested

Capital invested by funds: $150M → $68.7M (-$81.4M)

Holders
92
Holders Change
-8
Holders Change %
-8%
% of All Funds
2.05%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
23
Reduced
29
Closed
21
Calls
$38K
Puts
$34K
Net Calls
+$4K
Net Calls Change
-$624K

BLCM Hedge Fund Activity: Q4 2018 in Review

92 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q4 2018, worth a combined $68.7M — down 54% from $150M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of BLCM and 14 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 23 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.01M. The largest seller was Farallon Capital Management, cutting an estimated $5.04M.

  • 92 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q4 2018, down from 100 in Q3 2018.
  • Funds reported $68.7M of Bellicum Pharmaceuticals, Inc. stock for Q4 2018, down 54% quarter-over-quarter.
  • 14 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q4 2018 and 21 closed out, a net change of -7 holders.
  • The largest Bellicum Pharmaceuticals, Inc. buyer in Q4 2018 was Renaissance Technologies, an estimated $2.01M added.
  • The largest Bellicum Pharmaceuticals, Inc. seller in Q4 2018 was Farallon Capital Management, an estimated $5.04M sold.

Based on aggregated 13F filings for Q4 2018.